SMS Lifesciences India said it has completed disinvestment of up to 10% stake of Mahi Drugs and is raising fresh equity in Mahi Drugs, on a private placement basis.
Following the above transaction, Mahi Drugs will cease to be a wholly-owned subsidiary of the company but shall continue as a subsidiary company of the company with 60% equity stake.
The net profit of SMS Lifesciences India declined 13.70% to Rs 2.33 crore in Q3 FY22 over Q3 FY21. Net sales rose 36.79% to Rs 91.06 crore in Q3 FY22 as against Rs 66.57 crore during Q3 FY21.
SMS Lifesciences India is presently engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of organic & inorganic chemicals, pharmaceuticals, active pharmaceutical ingredients (API) and intermediates.
Shares of SMS Lifesciences India lost 0.67% to Rs 641.05 on BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app